Eric A. Ortlund is a professor of Biochemistry at Emory University School of Medicine and the Emory Vaccine Center. His lab uses structural, biochemical and biophysical approaches to study lipid signaling, transcriptional control and host--pathogen interactions. He is the Director of the Molecular and Systems Pharmacology program and Scientific Director of the Emory Integrated Metabolomics and Lipidomics Core.
Max Crispin is a professor of Glycobiology at the University of Southampton. Max read Biochemistry at Oriel as an undergraduate and, after doctoral studies at Oxford and Scripps Research, went on to run the Glycoprotein Therapeutics Laboratory within Oxford’s Department of Biochemistry. At Oriel College, he held a variety of roles including Tutorial Fellow in Biochemistry, Against Breast Cancer Senior Research Fellow, and Senior Dean, and is currently a Supernumerary Fellow. He has also been a lecturer in Biochemistry at Corpus Christi College. Max’s laboratory currently operates at the nexus of glycoprotein engineering and glycan analytics and is mainly focused on the design of antibody therapeutics against breast cancer and in supporting the development of vaccine candidates against viral pathogens, especially HIV.
Kalpana Luthra is a professor and the Head of the Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India. She completed her PhD at AIIMS in 1994 and joined as faculty at AIIMS in 1998. She was awarded the Shakuntala Amir Chand Prize by the Indian Council of Medical Research (ICMR) for the year 2003 and the Fogarty fellowship in 2002 and availed training in HIV-1 antibody-related work at New York University. She is a fellow of the National Academy of Medical Sciences India (NAMS), National Academy of Sciences, India (NASI), and the Indian National Science Academy (INSA). Her research work is focused on studying the evolution of HIV and host antibody responses by undertaking longitudinal studies in HIV-1-infected children and adults. For more than a decade, her team has been actively involved in the generation of recombinant human anti-HIV monoclonal antibodies (mAbs) of therapeutic potential. Her team has recently isolated a broadly neutralizing human anti-HIV-1 monoclonal antibody from an HIV-1-infected pediatric subject, to be tested for its therapeutic potential, and has contributed salient findings on the co-evolution of HIV-1 and host immune response in HIV-1-infected infants and children to the development of clade C-based vaccine design.
